Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 Fatty Acids for NASH in Type 2 Diabetes
NCT00323414Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Apr 2006
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing Opti-EPA with Placebo (2 arms). Primary endpoint: Number of Participants With Improvement of >= 2 Points in NAFLD Activity Score at 48 weeks. Started Apr 2006; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT00323414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00323414.